Verona Pharma plc VRNA NASDAQ

Verona Pharma plc (VRNA) reported exceptional year-over-year revenue growth of +20502.7% through 2025-06 (TTM revenue vs prior-year TTM). Net income showed exceptional earnings expansion of +32.8% YoY, reaching $9M in the latest quarter. The net profit margin is 11.6%, which is moderate. the company was profitable in 1 out of the last 4 quarters. The gross margin is 93.9% (high), up 16.2pp vs the prior year. With a $73B market cap, MOAT composite score of 76/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (15/100, Pass) — proving strong growth momentum
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 20-year annual history, the company was profitable in 1 of 20 years — a mixed long-term record
• INCOME (10/100, Partial) — the company is profitable but margin is below 15%
• MOAT (76/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 33/100 with 0/7 criteria passed.